Denali Therapeutics Reports Third Quarter 2026 Financial Results

Denali Therapeutics reported third-quarter 2026 net income of $70.1 million, including a one-time $194.0 million gain from selling a Priority Review Voucher. AVLAYAH generated $17.8 million in net product revenue, above the $12.2 million FactSet consensus, while earnings per share were $0.37 versus expectations for a $0.31 loss. The company forecast fourth-quarter revenue of $30.0 million to $32.0 million; AVLAYAH coverage exceeded 70% of U.S. commercial lives, and its permanent J-code took effect October 1.